411 related articles for article (PubMed ID: 21829025)
1. Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis.
Hayaishi S; Chung H; Kudo M; Ishikawa E; Takita M; Ueda T; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Ueshima K
Dig Dis; 2011; 29(3):326-32. PubMed ID: 21829025
[TBL] [Abstract][Full Text] [Related]
2. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis.
Kawaguchi T; Shiraishi K; Ito T; Suzuki K; Koreeda C; Ohtake T; Iwasa M; Tokumoto Y; Endo R; Kawamura NH; Shiraki M; Habu D; Tsuruta S; Miwa Y; Kawaguchi A; Kakuma T; Sakai H; Kawada N; Hanai T; Takahashi S; Kato A; Onji M; Takei Y; Kohgo Y; Seki T; Tamano M; Katayama K; Mine T; Sata M; Moriwaki H; Suzuki K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1012-8.e1. PubMed ID: 24036055
[TBL] [Abstract][Full Text] [Related]
3. A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma.
Takeshita S; Ichikawa T; Nakao K; Miyaaki H; Shibata H; Matsuzaki T; Muraoka T; Honda T; Otani M; Akiyama M; Miuma S; Ozawa E; Fujimito M; Eguchi K
Nutr Res; 2009 Feb; 29(2):89-93. PubMed ID: 19285598
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of early interventional therapy of branched-chain amino acid granules in patients with hepatocellular carcinoma: propensity score matching analysis.
Nishikawa H; Kita R; Kimura T; Ohara Y; Takeda H; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Osaki Y
Int J Oncol; 2014 Sep; 45(3):1082-90. PubMed ID: 24969042
[TBL] [Abstract][Full Text] [Related]
5. Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Kanekawa T; Nagai H; Kanayama M; Sumino Y
Cancer Chemother Pharmacol; 2014 Nov; 74(5):899-909. PubMed ID: 25138286
[TBL] [Abstract][Full Text] [Related]
6. Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T
J Gastroenterol Hepatol; 2015 Sep; 30(9):1412-9. PubMed ID: 25799910
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis.
Habu D; Nishiguchi S; Nakatani S; Lee C; Enomoto M; Tamori A; Takeda T; Ohfuji S; Fukushima W; Tanaka T; Kawamura E; Shiomi S
Hepatogastroenterology; 2009; 56(96):1719-23. PubMed ID: 20214224
[TBL] [Abstract][Full Text] [Related]
8. A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: validation using prognostic markers for pre-liver transplant status.
Kawamura E; Habu D; Morikawa H; Enomoto M; Kawabe J; Tamori A; Sakaguchi H; Saeki S; Kawada N; Shiomi S
Liver Transpl; 2009 Jul; 15(7):790-7. PubMed ID: 19562716
[TBL] [Abstract][Full Text] [Related]
9. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation.
Nishikawa H; Osaki Y; Iguchi E; Koshikawa Y; Ako S; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Sakamoto A; Henmi S; Hatamaru K; Ishikawa T; Saito S; Nasu A; Kita R; Kimura T
J Clin Gastroenterol; 2013 Apr; 47(4):359-66. PubMed ID: 23090049
[TBL] [Abstract][Full Text] [Related]
10. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
11. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial.
Poon RT; Yu WC; Fan ST; Wong J
Aliment Pharmacol Ther; 2004 Apr; 19(7):779-88. PubMed ID: 15043519
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of granular BCAA after hepatectomy for liver cancer complicated with liver cirrhosis.
Togo S; Tanaka K; Morioka D; Sugita M; Ueda M; Miura Y; Kubota T; Nagano Y; Matsuo K; Endo I; Sekido H; Shimada H
Nutrition; 2005 Apr; 21(4):480-6. PubMed ID: 15811769
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis.
Muto Y; Sato S; Watanabe A; Moriwaki H; Suzuki K; Kato A; Kato M; Nakamura T; Higuchi K; Nishiguchi S; Kumada H;
Clin Gastroenterol Hepatol; 2005 Jul; 3(7):705-13. PubMed ID: 16206505
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of supplementation with branched-chain amino acids on postoperative bacteremia in living donor liver transplant recipients.
Shirabe K; Yoshimatsu M; Motomura T; Takeishi K; Toshima T; Muto J; Matono R; Taketomi A; Uchiyama H; Maehara Y
Liver Transpl; 2011 Sep; 17(9):1073-80. PubMed ID: 21542128
[TBL] [Abstract][Full Text] [Related]
15. Impact of Branched-Chain Amino Acid-Enriched Nutrient on liver Cirrhosis with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization in Barcelona Clinic Liver Cancer Stage B: A Prospective Study.
Shiozawa S; Usui T; Kuhara K; Tsuchiya A; Miyauchi T; Kono T; Asaka S; Yamaguchi K; Yokomizo H; Shimakawa T; Yoshimatsu K; Katsube T; Naritaka Y
J Nippon Med Sch; 2016; 83(6):248-256. PubMed ID: 28133005
[TBL] [Abstract][Full Text] [Related]
16. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study.
Les I; Doval E; García-Martínez R; Planas M; Cárdenas G; Gómez P; Flavià M; Jacas C; Mínguez B; Vergara M; Soriano G; Vila C; Esteban R; Córdoba J
Am J Gastroenterol; 2011 Jun; 106(6):1081-8. PubMed ID: 21326220
[TBL] [Abstract][Full Text] [Related]
17. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
18. Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: A randomized trial.
Nojiri S; Fujiwara K; Shinkai N; Iio E; Joh T
Nutrition; 2017 Jan; 33():20-27. PubMed ID: 27908546
[TBL] [Abstract][Full Text] [Related]
19. Effects of branched-chain amino acids-enriched nutrient support for patients undergoing liver resection for hepatocellular carcinoma.
Okabayashi T; Nishimori I; Sugimoto T; Maeda H; Dabanaka K; Onishi S; Kobayashi M; Hanazaki K
J Gastroenterol Hepatol; 2008 Dec; 23(12):1869-73. PubMed ID: 18717761
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.
N'Kontchou G; Paries J; Htar MT; Ganne-Carrie N; Costentin L; Grando-Lemaire V; Trinchet JC; Beaugrand M
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1062-8. PubMed ID: 16844421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
